What do systematic reviews say?

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in overall survival (Duration of (high certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.84, 1.05]
  4 studies · 3848 participants
  High

Intervention not reported

The intervention showed no clear difference in progression‐free survival (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.86, 1.03]
  5 studies · 3861 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 1‐year survival rate  (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.96, 1.08]
  7 studies · 4420 participants
  Low

Intervention not reported

The intervention showed no clear difference in overall survival: 2‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.02 [0.93, 1.12]
  7 studies · 4420 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 3‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 0.99 [0.9, 1.09]
  7 studies · 4420 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in overall survival: 5‐year survival rate (moderate certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 0.98 [0.86, 1.12]
  7 studies · 4389 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in adverse events: any (Duration of (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.97, 1.28]
  4 studies · 4126 participants
  Low

Intervention not reported

The intervention showed no clear difference in adverse events: severe, grade > 2 (Duration of (low certainty).

• Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or… 2021 · Cochrane Headline outcomes only
  RR 1.14 [0.92, 1.4]
  6 studies · 4546 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

The review found no eligible studies for this question.

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 21642 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

The review found no eligible studies for this question.

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

• Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  23 studies · 16065 participants
  Very low